Dossier - Page 1 - FirstWord Reports

Learn More The Orphan Drug Fact File [2020]

Everything you need to know about current activity and new opportunities in orphan drugs Over 7,600 orphan drug designations covered in a flexible data file A detailed report providing 12 in-depth therapy-based...

Compare
Learn More Market Access Team Structure and Function (2020)

How are market access teams achieving success in today's challenging market? In the light of unprecedented operational challenges, the pressure on market access teams continues to build as the specific needs of multiple...

Compare
Learn More Big Data and AI in Market Access [2020]

How is big data+AI technology driving market access strategy and practice? Juggling the demands of multiple stakeholders for evidence of utility and value, while harnessing the insights from an ever-growing number of...

Compare
Learn More Ambitions in Health: Tech Giants [2020]

The march of tech giants in healthcare continues—but to what end? COVID-19 has accelerated the digital health agenda and raised stakeholder awareness of the value of technology across the healthcare landscape. As...

Compare
Learn More Pricing and Reimbursement in Respiratory: Payer Views [2020]

How have payers met the challenge of COVID-19 and how do they see the future? The impact of the COVID-19 pandemic has been especially felt in respiratory disease and presents a unique set of challenges for payers. From...

Compare
Learn More Innovations in Drug Pricing and Reimbursement 2020

Evaluating new digital tools and deal structures to drive better commercial outcomes What are the trends and technologies that could deliver a better understanding of payers' needs and build improved evidence of value?...

Compare
Learn More Data Driven Customer Relationship Management In Pharma

Experts agree data-driven CRM holds the key to achieving true customer centricity It's already known that data-driven CRM improves and drives forward the customer experience. Pharma has a powerful tool at its disposal,...

Compare
Learn More Real World Data for Orphan Drugs: Meeting the Data Analysis Challenge

Creating meaningful insights from diverse data sources The explosion in real-world data (RWD) from digital platforms is creating new insights into the understanding of rare diseases and patient experiences. The value...

Compare
Learn More The Future of Decentralised Clinical Trials

COVID-19 has driven innovation in clinical trials, but what happens next and how can pharma prepare? Pre-pandemic many companies were curious to explore the potential of decentralized clinical trials (DCTs), but now see...

Compare
Learn More Trends in KOL Experience Management [2020]

Is your MSL team delivering an outstanding KOL experience? KOL support and insights are critical to pharma, and MSLs are charged with delivering a service that keeps them fully informed and engaged. But how do you...

Compare
Learn More Pricing and Reimbursement in Neurology: Payer Views [2020]

Understanding payer challenges in Multiple Sclerosis, Epilepsy, Migraine and Neurodegenerative disease Despite wide unmet need across a number of neurological conditions, no really high impact breakthrough therapies...

Compare
Learn More Virtual Medical Conferences: The new normal?

Is the virtual medical conference here to stay? The crowded world of medical conferences was already ripe for change when the COVID-19 pandemic hit. Conference organizers responded quickly, rapidly accelerating their...

Compare
Learn More Remote Patient Monitoring: Pharma’s challenge and opportunity

Lessons for pharma as remote patient monitoring drives fundamental change in disease prevention and management. Accelerated by COVID-19, use of remote patient monitoring (RPM) technology has grown rapidly. Increasingly...

Compare
Learn More Value-based Healthcare in a Digital World [2020]

Accelerated use of digital technology challenges pharma to rethink its approach COVID-19 has radically increased the use of digital technology by patients and HCPs but how does that play into the trend to value-based...

Compare
Learn More Orphan Drugs: Benchmarking Commercial Models [2020]

What are the essential factors for orphan drug success? Several orphan drugs have proven to be commercial winners, so what are the key ingredients for success in 2020? For example, as the sector has evolved the power...

Compare
Learn More Trends in Digital Pharma Marketing (2020)

How has COVID-19 impacted pharma digital marketing activity—now and for the future? The effects of coronavirus on pharma marketing budgets, priorities and actions cannot be ignored. During the pandemic, pharma...

Compare
Learn More MSL-KOL Engagement [2020]

Maintaining and growing KOL relationships in pandemic lockdown At a stroke, the COVID-19 pandemic shut down MSL's principal KOL engagement channels. With face-to-face interactions on hold, MSLs have turned to...

Compare
Learn More The Rise of ICER – The Payer Perspective

Payers reveal where ICER is really impacting pharma/payer relations How is the Institute for Clinical and Economic Review (ICER) influencing payer behavior? ICER's evidence and price benchmarking data are valued by...

Compare
Learn More The State of Pharma Digital Transformation 2020

How far has pharma come, and what does it still need to do, to realize the full benefits of digital technology across its business? The COVID-19 pandemic may have spurred rapid expansion in the use of digital tools but...

Compare
Learn More Telemedicine’s Move into the Mainstream

COVID-19 accelerated uptake of telemedicine is rapidly transforming healthcare delivery Telemedicine is one major success story of the pandemic. Barriers previously hindering widespread adoption of telehealth practices...

Compare

Browse by